Cholesterol and LDL reduction (FDA-approved claim)
Oat beta-glucan has an FDA-approved health claim for reducing coronary heart disease risk — requiring 3 g/day soluble beta-glucan from oats or barley. Meta-analyses of 80+ RCTs confirm significant reductions in total cholesterol (by 5–10%) and LDL cholesterol (by 7–13%) — the most extensively studied dietary fiber for cardiovascular risk reduction.
Blood sugar and glycemic control
Oat beta-glucan's viscous gel slows gastric emptying and reduces postprandial glucose and insulin responses. FDA also recognizes a qualified health claim for beta-glucan and diabetes risk reduction. Clinical studies show consistent reductions in fasting glucose, postprandial glucose, and insulin sensitivity improvement in diabetic and pre-diabetic patients.
Immune system activation (yeast-derived)
Yeast beta-1,3/1,6-glucans bind Dectin-1 and CR3 receptors on macrophages and neutrophils, activating innate immune responses without triggering inflammation. Wellmune® clinical trials show reduced incidence and severity of upper respiratory infections, reduced cold and flu symptoms, and improved immune surveillance markers in healthy adults.
Gut microbiome and prebiotic support
Beta-glucans are selectively fermented by beneficial gut bacteria — particularly Bifidobacterium, Lactobacillus, and Roseburia — producing short-chain fatty acids including butyrate. This prebiotic activity improves gut microbiome diversity, supports colonocyte energy, reduces colonic inflammation, and complements the direct fiber effects on cholesterol and glucose metabolism.
Viscous gel formation and bile acid sequestration
Oat and barley beta-glucans dissolve in the GI tract to form a highly viscous gel that physically traps bile acids and slows nutrient absorption. The depletion of the bile acid pool forces hepatic cholesterol conversion to new bile acids, reducing serum cholesterol and upregulating LDL receptors — the mechanism underlying the FDA-approved cardiovascular health claim.
Dectin-1 and CR3 receptor immune activation
Yeast beta-1,3/1,6-glucans bind Dectin-1 (a C-type lectin receptor) and complement receptor 3 (CR3/CD11b) on macrophages, neutrophils, and dendritic cells. Dectin-1 activation triggers Syk kinase signaling and NLRP3 inflammasome priming — activating innate immune killing capacity and cytokine production that primes the immune system for enhanced pathogen clearance.
Short-chain fatty acid production via colonic fermentation
Gut bacteria ferment beta-glucans to produce acetate, propionate, and butyrate in the colon. Propionate travels to the liver via portal vein, inhibiting lipogenesis and gluconeogenesis. Butyrate feeds colonocytes and activates PPAR-γ and GPR109A receptors, reducing intestinal inflammation and maintaining the gut barrier — providing both metabolic and immune benefits.
Comprehensive meta-analysis of 80 randomized controlled trials examining oat beta-glucan effects on blood lipids.
Pooled data from 80 RCTs across diverse populations.
Oat beta-glucan (3 g/day) significantly reduced LDL cholesterol by an average of 4.2% (range: 3–10% depending on dose and baseline). Total cholesterol reduced proportionally. Consistent effects across all 80 trials. Basis for FDA health claim. Well-tolerated.
Randomized, double-blind, placebo-controlled trial of Wellmune® (250 mg/day yeast beta-glucan) vs. placebo in 100 healthy adults during cold and flu season for 90 days.
100 healthy adults during winter cold/flu season. 90-day intervention.
Wellmune® group showed significantly fewer upper respiratory infection days, lower symptom severity scores, and improved quality of life vs. placebo. NK cell activity significantly increased. Supports yeast beta-glucan for seasonal immune support.